Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chromadex Corp CDXC

Technology Scientific & Technical Instruments
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished... see more

Recent & Breaking News (NDAQ:CDXC)

Published studies in humans and mice reveal how a superior vitamin B3 may play an important role in helping us enjoy longer, healthier lives

GlobeNewswire October 10, 2016

ChromaDex Adds New AnthOrigin™ to Its Proprietary Ingredient Portfolio

GlobeNewswire October 3, 2016

Leading Supplement Retailer Features NIAGEN® as Their Hot Ingredient for Fall, 2016

GlobeNewswire September 22, 2016

Update: ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016

GlobeNewswire September 15, 2016

ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016

GlobeNewswire September 15, 2016

ChromaDex to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016

GlobeNewswire August 30, 2016

ChromaDex Corp. (Nasdaq: CDXC) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire May 5, 2016

ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016

GlobeNewswire April 28, 2016

ChromaDex to Begin Trading on The NASDAQ Capital Market Today

GlobeNewswire April 25, 2016

ChromaDex Announces Reverse Stock Split as Company Seeks to List its Common Stock on The NASDAQ Capital Market

GlobeNewswire April 12, 2016

ChromaDex Reports 2015 Record Revenue as Ingredient Sales Grew 83%

GlobeNewswire March 17, 2016

Analyzing the Price Movement - Analyst Research on American Green, Goodrich Petroleum, Anglo American and Chromadex

Accesswire March 15, 2016

ChromaDex to Report Year End 2015 Financial Results on Thursday, March 17, 2016

GlobeNewswire March 10, 2016

ChromaDex Initiates Second Human Clinical Study on NIAGEN® -The World's First and Only Commercially Available Form of Nicotinamide Riboside (NR)

GlobeNewswire March 10, 2016

Analyst Insight on Equities in Limelight - Comprehensive Research on Dajin Resources, Experience Art and Design, Chromadex, and American Riding Tours

Accesswire March 9, 2016

What's Driving the Price Movement - Featured Research on Virtus Oil and Gas, MedeFile International, Chromadex and Reckitt Benckiser Group

Accesswire March 7, 2016

ChromaDex to Present at the 28th Annual ROTH Conference on March 15, 2016

GlobeNewswire March 1, 2016

ChromaDex Announces Commencement of an Obesity-Related Clinical Study of NIAGEN® in Collaboration With the University of Copenhagen and Aarhus University

GlobeNewswire February 22, 2016

ChromaDex Named to 2016 OTCQX Best 50

Press Releases February 17, 2016

What's Directing Investors Movement -- Consensus Reports on Hemp, Penn Virginia, Chromadex, and Newcrest Mining

Accesswire February 2, 2016